Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.

PURPOSE The biological behaviour of prostate cancer is highly variable and prediction by the commonly employed prognostic parameters is not sufficient. The concept of neuroendocrine (NE) differentiation in prostate adenocarcinoma has recently received increasing attention due to possible implications for prognosis and therapy. MATERIALS AND METHODS Core needle biopsies from 142 newly diagnosed patients were immunohistochemically examined for the coexistence of NE differentiation using an antibody against chromogranin A (CgA). Circulating CgA was available in 106 of these patients. RESULTS NE differentiation was found in 64 (45.1%) tumors. Among them 29 (20.4%) had CgA positive cells scattered or focally distributed in less than 5% per mm3 of tumor tissues, 26 (18.3%) between 5% and 10% and 9 (6.4%) more than 10%, respectively. There was a significant correlation between the extent of NE features and either Gleason score (P < 0.01) or stage of disease. Circulating CgA but not PSA correlated with immunohistochemical CgA (P < 0.03) particularly in metastatic cases. CONCLUSIONS These data support the concept that NE differentiation in human prostate cancer has a negative prognostic significance. Circulating CgA levels reflect immunohistochemical findings.

[1]  P. Abrahamsson.  Neuroendocrine cells in tumour growth of the prostate. , 1999, Endocrine-related cancer.

[2]  P. A. Sant'agnese,et al.  Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects , 1998 .

[3]  G. Pruneri,et al.  Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: Neuroendocrine expression in patients untreated and treated with androgen deprivation therapy , 1998, The Prostate.

[4]  P. di Sant'Agnese,et al.  Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma , 1998, The Prostate. Supplement.

[5]  H. Bonkhoff.  Neuroendocrine cells in benign and malignant prostate tissue: Morphogenesis, proliferation, and androgen receptor status , 1998, The Prostate. Supplement.

[6]  P. di Sant'Agnese,et al.  Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects. , 1998, Urology.

[7]  T. H. van der Kwast,et al.  The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.

[8]  M. Stridsberg,et al.  Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? , 1997, The Prostate.

[9]  P. di Sant'Agnese,et al.  Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. , 1996, Urology.

[10]  L. Baert,et al.  Morphologic and neuroendocrine features of adenocarcinoma arising in the transition zone and in the peripheral zone of the prostate. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[11]  T. H. van der Kwast,et al.  The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long‐term follow‐up study with patients treated by radical prostatectomy , 1995, International journal of cancer.

[12]  D. Bostwick,et al.  Neuroendocrine Differentiation in Prostatic Intraepithelial Neoplasia and Adenocarcinoma , 1994, The American journal of surgical pathology.

[13]  V. Speights,et al.  Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression , 1994, Cancer.

[14]  V. Reuter,et al.  Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma , 1993, Cancer.

[15]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .

[16]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma , 1992 .

[17]  D. Gleason,et al.  Histologic grading of prostate cancer: a perspective. , 1992, Human pathology.

[18]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in human prostatic carcinoma. , 1992, Human pathology.

[19]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications , 1992, Cancer.

[20]  C. Logothetis,et al.  The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma , 1992, Journal of cellular biochemistry. Supplement.

[21]  R. Cohen,et al.  Neuro-endocrine cells--a new prognostic parameter in prostate cancer. , 1991, British journal of urology.

[22]  M. Ciomei,et al.  Bombesin stimulates growth of human prostatic cancer cells in vitro , 1990, Cancer.

[23]  L. Grimelius,et al.  The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an "endocrine marker". , 1989, Pathology, research and practice.

[24]  M. Papotti,et al.  Neuroendocrine differentiation in carcinomas of the breast: a study of 51 cases. , 1989, Seminars in diagnostic pathology.

[25]  M. Dauge,et al.  A.P.U.D. type endocrine tumour of the prostate. Incidence and prognosis in association with adenocarcinoma. , 1987, Progress in clinical and biological research.

[26]  A. Bono,et al.  Endocrine-paracrine cells in prostatic carcinoma and clinical course of the disease. , 1985, European urology.

[27]  W. Whitmore.  Natural history and staging of prostate cancer. , 1984, The Urologic clinics of North America.

[28]  C. Capella,et al.  The endocrine component of prostatic carcinomas, mixed adenocarcinoma‐carcinoid tumours and non‐tumour prostate. Histochemical and ultrastructural identification of the endocrine cells , 1981, Histopathology.